FR3134960B3 - Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson - Google Patents

Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson Download PDF

Info

Publication number
FR3134960B3
FR3134960B3 FR2204012A FR2204012A FR3134960B3 FR 3134960 B3 FR3134960 B3 FR 3134960B3 FR 2204012 A FR2204012 A FR 2204012A FR 2204012 A FR2204012 A FR 2204012A FR 3134960 B3 FR3134960 B3 FR 3134960B3
Authority
FR
France
Prior art keywords
risk
treatment
parkinson
disease
alert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2204012A
Other languages
English (en)
Other versions
FR3134960A3 (fr
Inventor
Christopher Cala
François Meunier
Habiboulaye Amadou-Boubacar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide SA, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical Air Liquide SA
Priority to FR2204012A priority Critical patent/FR3134960B3/fr
Publication of FR3134960A3 publication Critical patent/FR3134960A3/fr
Application granted granted Critical
Publication of FR3134960B3 publication Critical patent/FR3134960B3/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • General Business, Economics & Management (AREA)
  • Pathology (AREA)
  • Business, Economics & Management (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Titre de l’invention Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson L’invention concerne un système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson par un patient atteint de ladite maladie de Parkinson et suivant un traitement par perfusion d’apomorphine au moyen d’une pompe de perfusion. Des moyens de détermination permettent de déterminer un ou des paramètres de la pompe de perfusion, à savoir concentration en apomorphine, durée de perfusion et dose totale perfusée. Des moyens de traitement informatique à processeur permettent de traiter le ou les paramètres au moyen d’un premier modèle mathématique prédéfini pour en déduire un score de risque d’abandon du traitement par le patient. Des moyens d’alerte déclenchent une alerte de risque d’abandon du traitement lorsque le score de risque excède un seuil d’alerte donné préfixé. Des moyens d’affichage affichent notamment ce score de risque. Préférentiellement, un second modèle mathématique permet de calculer une recommandation d'action en cas d'alerte. Figure de l’abrégé : Fig. 1
FR2204012A 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson Active FR3134960B3 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2204012A FR3134960B3 (fr) 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2204012A FR3134960B3 (fr) 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson
FR2204012 2022-04-28

Publications (2)

Publication Number Publication Date
FR3134960A3 FR3134960A3 (fr) 2023-11-03
FR3134960B3 true FR3134960B3 (fr) 2024-05-03

Family

ID=88519912

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2204012A Active FR3134960B3 (fr) 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson

Country Status (1)

Country Link
FR (1) FR3134960B3 (fr)

Also Published As

Publication number Publication date
FR3134960A3 (fr) 2023-11-03

Similar Documents

Publication Publication Date Title
JP7398031B2 (ja) 治療用血漿タンパク質投与計画を提供するための方法、およびマシンアクセス可能デバイス
Nutt et al. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon
Singh et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience
Nolan et al. Hemolysis-associated priapism in sickle cell disease
TWI672602B (zh) 提供藥物動力學藥物給藥方案的方法和設備
Kee Phenylephrine infusions for maintaining blood pressure during spinal anesthesia for cesarean delivery: finding the shoe that fits
EP1930039A2 (fr) Système pour détécter des occlusions de manière rapide dans une pompe à seringue
Aaronson et al. Relationship between prolonged intraocular inflammation and macular edema after cataract surgery
Boyle et al. The role of inflammation in acute psychosocial stress-induced modulation of reward processing in healthy female adults
DE60322084D1 (de) Vorrichtung und verfahren zur qualitativen und quantitativen bestimmung von intravenösen flüssigkeitskomponenten
Patriquin et al. Long-term safety and efficacy of pegcetacoplan treatment in adults with paroxysmal nocturnal hemoglobinuria
Hua et al. Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B
Otero et al. Exploring apixaban pharmacokinetics, pharmacodynamics, and safety in hemodiafiltration patients
Tamura et al. In vivo evaluation of ocular inflammatory responses in experimental diabetes
Kamri Comparison of the safety effects of antiplatelets on the kidneys in patients with vascular disease
WO2022140012A1 (fr) Système de surveillance du sang pour la détection d'hémorragies occultes
WO2013015714A1 (fr) Procédé pour traiter l'hépatite c virale chronique
US20070112329A1 (en) Infiltration detection system
Hibbert et al. Understanding hepatitis C virus reinfections in England in the context of eliminating viral hepatitis as a public health concern
Muntean et al. Pharmacokinetic proofs on interaction between Zolpidem and Phenytoin: a two-treatment, two-period study in healthy male subjects
Villgran et al. An Unusual Case of Eosinophilic Pleural Effusion and Rivaroxaban Hypersensitivity
Barratt et al. Atacicept in IgA Nephropathy (IgAN): Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs. Placebo with a Focus on COVID-19: SA-PO884
Fontana et al. Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study
Quirk Development of a Method to Assess the Impact of Saline Infusion on Venous Physiology and Injury in Humans
Atkinson et al. Gabapentin for chronic back pain: a randomized clinical trial

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4